Megan Wind-Rotolo

List of Publications by Year
in descending order

17 papers	5,281 citations	759055 12 h-index	1058333 14 g-index
17 all docs	17 docs citations	17 times ranked	7541 citing authors

#	Article	IF	Citations
1	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	13.9	3,334
2	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	6.0	898
3	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	15.2	488
4	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	5.8	84
5	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184.	3.2	80
6	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunology Research, 2021, 9, 1202-1213.	1.6	71
7	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncology, The, 2022, 23, 172-184.	5.1	58
8	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1371-1380.	3.2	49
9	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
10	Myeloid Cellâ€"associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clinical Cancer Research, 2021, 27, 4287-4300.	3.2	42
11	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
12	A Machineâ€Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma. Clinical Pharmacology and Therapeutics, 2020, 107, 978-987.	2.3	23
13	Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. , 2021, 9, e001506.		23
14	Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma. Cancer Research, 2019, 79, CT037-CT037.	0.4	16
15	FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.. Journal of Clinical Oncology, 2017, 35, TPS4137-TPS4137.	0.8	15
16	The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. European Journal of Cancer, 2018, 103, 259-266.	1.3	13
17	Misannotated Multi-Nucleotide Variants in Public Cancer Genomics Datasets Lead to Inaccurate Mutation Calls with Significant Implications. Cancer Research, 2021, 81, 282-288.	0.4	7